维立志博-B(09887)：LBL-024于一线治疗胆道癌II期试验的首例患者用药

智通财经10-27

智通财经APP讯，维立志博-B(09887)发布公告，评价奥帕替苏米单抗(PD-L1/4-1BB双特异性抗体LBL-024)用于一线治疗胆道癌的II期临床试验首例患者已成功用药，标志着该核心产品适应症拓展高效推进。本次开展的开放标签、多中心II期临床研究由复旦大学附属中山医院周俭教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗联合用药一线治疗晚期胆道癌患者的疗效及安全性。LBL-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2578614963?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-27 18:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578614963","market":"us","top_or_hot":-1,"title":"维立志博-B(09887)：LBL-024于一线治疗胆道癌II期试验的首例患者用药","media":"智通财经","content":"<div>\n<p>智通财经APP讯，维立志博-B(09887)发布公告，评价奥帕替苏米单抗(PD-L1/4-1BB双特异性抗体LBL-024)用于一线治疗胆道癌的II期临床试验首例患者已成功用药，标志着该核心产品适应症拓展高效推进。本次开展的开放标签、多中心II期临床研究由复旦大学附属中山医院周俭教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗联合用药一线治疗晚期胆道癌患者的疗效及安全性。LBL-...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1360491.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>维立志博-B(09887)：LBL-024于一线治疗胆道癌II期试验的首例患者用药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n维立志博-B(09887)：LBL-024于一线治疗胆道癌II期试验的首例患者用药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-27 18:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1360491.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，维立志博-B(09887)发布公告，评价奥帕替苏米单抗(PD-L1/4-1BB双特异性抗体LBL-024)用于一线治疗胆道癌的II期临床试验首例患者已成功用药，标志着该核心产品适应症拓展高效推进。本次开展的开放标签、多中心II期临床研究由复旦大学附属中山医院周俭教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗联合用药一线治疗晚期胆道癌患者的疗效及安全性。LBL-...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1360491.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1360491.html","article_id":"2578614963","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578614963","pubTimestamp":1761559909,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，维立志博-B 发布公告，评价奥帕替苏米单抗用于一线治疗胆道癌的II期临床试验首例患者已成功用药，标志着该核心产品适应症拓展高效推进。LBL-024是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09887":"维立志博-B","BK1161":"生物科技"},"translate_title":"Weilizhibo-B (09887): LBL-024 was used in the first patient in a phase II trial for the first-line treatment of biliary tract cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1.5},"content_text":"智通财经APP讯，维立志博-B(09887)发布公告，评价奥帕替苏米单抗(PD-L1/4-1BB双特异性抗体LBL-024)用于一线治疗胆道癌的II期临床试验首例患者已成功用药，标志着该核心产品适应症拓展高效推进。本次开展的开放标签、多中心II期临床研究由复旦大学附属中山医院周俭教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗联合用药一线治疗晚期胆道癌患者的疗效及安全性。LBL-024是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。LBL-024亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。凭藉我们专有的X-bodyTM平台， LBL-024采用最佳的2:2结构设计，可解除PD-1/L1免疫抑制并强化4-1BB调节的T 细胞激活，实现协同消灭肿瘤的效果，具有较PD-1/L1抑制剂更强的广谱癌症治疗潜力。本公司于2024年4月获得国家药品监督管理局(NMPA)批准开展单臂注册临床试验，于2024年10月自NMPA获得LBL-024治疗后线晚期肺外神经内分泌癌的突破性疗法认定(BTD)，并于2024年11月自美国食品药品监督管理局(FDA)获得 LBL-024治疗神经内分泌癌的孤儿药认定(ODD)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578614963","isCrawlerRequest":true}